Nisha Pandey

Ozempic & Wegovy Maker To Evaluate Long-Acting GLP-1 Implant That Could Last Up To A Year

Ozempic & Wegovy Manufacturer To Evaluate Long-Acting Semaglutide Implant That Could Last Up To A Year

<span>Novo Nordisk</span>, the maker of GLP-1 medicines like <span>Ozempic</span> and <span>Wegovy</span>, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections. 

The Danish pharma company has partnered with Vivani Medical to evaluate an experimental long-acting GLP-1 implant (<span>semaglutide</span>) that could release the medication continuously for up to a year. 

If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.

<h2>What Is The Semaglutide Implant? </h2>

The implant, known as NPM-139, is a miniature device developed using Vivani's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period. 

According to Vivani, the goal is to provide consistent drug delivery with once- or twice-yearly dosing, with the long-term ambition of supporting treatment that could last up to a year from a single implant. However, the technology is still in development. 

Adam Mendelsohn, Ph.D., President and CEO of Vivani Medical said, “The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary.”

Also read: <a href="https://www.healthandme.com/health-news/wegovy-weight-loss-pill-available-in-uk-pharmacies-from-today-all-you-should-know-article-154949001" data-type="tilCustomLink">Wegovy Weight Loss Pill Available in UK Pharmacies From Today: All You Should Know</a>

<h2>Why GLP-1 Implant Could Be Groundbreaking? </h2>

GLP-1 medications like <a href="https://www.healthandme.com/health-news/demand-for-wegovy-weight-loss-pills-could-increases-the-risk-of-dangerous-counterfeits-survey-article-154953255" data-type="tilCustomLink">Ozempic and Wegovy</a> have transformed obesity treatment by helping people lose significant amounts of weight while also improving blood sugar control. However, these medications require regular injections, which can affect long-term adherence. 

Research has shown that many patients discontinue GLP-1 therapy within the first year because of factors like treatment fatigue, gastrointestinal side effects, cost, and the inconvenience of ongoing injections. 

An implant capable of delivering semaglutide continuously for months together could help by reducing dosing frequency and maintaining more consistent drug levels.

Fatty Liver Isn’t Just Alcohol: Dr V Mohan Busts Common Myths

<h2>The Rise Of GLP-1 Therapies In Obesity Treatment </h2>

The obesity drug market is rapidly evolving. With the advent of GLP-1 medications, the number of users who have tried this therapy is at an all-time high. According to Gallup's latest National Health and Well-Being Index, 11% of U.S. adults currently use a GLP-1 medication for weight loss. In 2024, this number was just 3%. 

The survey also said that 15% of adults have tried a GLP-1 medication at some point, compared to the 6% from two years ago. 

With the ever-increasing demand, researchers are investigating oral GLP-1 medicines, monthly injections, combination therapies, and now long-acting implants that could reduce the number of treatments patients need each year. 

While the yearly semaglutide implant is still an experimental concept, Novo Nordisk's decision to evaluate the technology highlights growing industry interest in making <a href="https://www.healthandme.com/nutrition/why-sustainable-weight-loss-requires-more-than-cutting-calories-article-154939060" data-type="tilCustomLink">obesity treatment</a> simpler and easier for patients to maintain in the long run.

Health Conditions A-Z

health

ozempic-wegovy-manufacturer-to-evaluate-long-acting-semaglutide-implant-that-could-last-up-to-a-year

glp 1

glp 1 drugs

glp 1 implant

Semaglutide

semaglutide weight loss

Semaglutide  implant

Novo Nordisk

ozempic

wegovy

wegovy and ozempic

bryan-johnson-plans-to-create-bryan-in-a-dish-living-lab-to-test-experimental-autoimmune-treatments

Bryan Johnson Plans To Create 'Bryan In A Dish' Living Lab To Test Experimental Autoimmune Treatments

west-nile-virus-detected-in-mosquitoes-in-us-why-health-officials-are-urging-people-to-stay-vigilant

West Nile Virus Detected in Mosquitoes in US; Why Health Officials Are Urging People to Stay Vigilant

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Novo Nordisk, the maker of GLP-1 medicines like Ozempic and Wegovy, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections. The Danish pharma company has partnered with Vivani Medical to evaluate an experimental long-acting GLP-1 implant (semaglutide) that could release the medication continuously for up to a year. If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity. What Is The Semaglutide Implant? The implant, known as NPM-139, is a miniature device developed using Vivani's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period. According to Vivani, the goal is to provide consistent drug delivery with once- or twice-yearly dosing, with the long-term ambition of supporting treatment that could last up to a year from a single implant. However, the technology is still in development. Adam Mendelsohn, Ph.D., President and CEO of Vivani Medical said, “The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary.”Also read: Wegovy Weight Loss Pill Available in UK Pharmacies From Today: All You Should KnowWhy GLP-1 Implant Could Be Groundbreaking? GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment by helping people lose significant amounts of weight while also improving blood sugar control. However, these medications require regular injections, which can affect long-term adherence. Research has shown that many patients discontinue GLP-1 therapy within the first year because of factors like treatment fatigue, gastrointestinal side effects, cost, and the inconvenience of ongoing injections. An implant capable of delivering semaglutide continuously for months together could help by reducing dosing frequency and maintaining more consistent drug levels.            The Rise Of GLP-1 Therapies In Obesity Treatment The obesity drug market is rapidly evolving. With the advent of GLP-1 medications, the number of users who have tried this therapy is at an all-time high. According to Gallup's latest National Health and Well-Being Index, 11% of U.S. adults currently use a GLP-1 medication for weight loss. In 2024, this number was just 3%. The survey also said that 15% of adults have tried a GLP-1 medication at some point, compared to the 6% from two years ago. With the ever-increasing demand, researchers are investigating oral GLP-1 medicines, monthly injections, combination therapies, and now long-acting implants that could reduce the number of treatments patients need each year. While the yearly semaglutide implant is still an experimental concept, Novo Nordisk's decision to evaluate the technology highlights growing industry interest in making obesity treatment simpler and easier for patients to maintain in the long run.

ozempic & wegovy manufacturer to evaluate long-acting semaglutide implant that could last up to a year

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Ozempic & Wegovy Maker To Evaluate Long-Acting GLP-1 Implant That Could Last Up To A Year

Bryan Johnson Plans To Create 'Bryan In A Dish' Living Lab To Test Experimental Autoimmune Treatments

West Nile Virus Detected in Mosquitoes in US; Why Health Officials Are Urging People to Stay Vigilant

India's Parliamentary Panel Calls For Doubling Ayushman Bharat Cover To Rs 10 Lakh

Health Conditions A-Z